Wolfe Research analyst Kalpit Patel initiated coverage of Exelixis (EXEL) with a Peer Perform rating and no price target Zanzalintinib is unlikely to fully replenish cabozantinib’s potential lost revenues, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL: